2019 ANNUAL REPORT amfAR, The Foundation for AIDS Research Cover photo: Human cells. 3D illustration © Ustyna Shevhcuk | Dreamstime.com Contents

amfAR in 2019 01

Grants, Fellowships, and Awards 09

Research Grants, Fellowships, and Awards

TREAT Asia Grants and Awards

Public Policy Awards

Financial Highlights 15

Leadership and Advisory Committees 17

Board of Trustees

Scientific Advisory Committee

Program Advisory Council

Management Group

Our Mission: amfAR, The Foundation for AIDS Research, is dedicated to ending the global AIDS epidemic through innovative research. HIGHLIGHTS

RESEARCH edge technology to address the main barrier to an HIV cure: the persistent reservoirs of virus not cleared by antiretroviral therapy (ART). Totaling $800,000, this new round of Investment grants launched the critical third phase of a research project begun Countdown to a Cure for AIDS in 2017. In 2015, amfAR launched its Countdown to a Cure for AIDS initiative, which is aimed at developing the scientific basis for a cure. To date, In the first two phases of her study, Dr. Hui Zhang of Johns amfAR has awarded 79 Countdown grants totaling more than $48 Hopkins University used mass spectrometry to scan the surface of million to support research conducted by 277 scientists working human cells for proteins—biomarkers—that discriminate between at 95 institutions in 15 countries. Structured to provide sustained latently infected and uninfected cells. After scanning a variety support for a wide range of studies that advance both emerging and of cell lines, she identified 17 potential targets. In phase three, established ideas, the strategy comprises the following components: Dr. Zhang is teaming up with HIV scientist Dr. Weiming Yang, also of Johns Hopkins University, to determine in a preclinical u The amfAR Institute for HIV Cure Research was established study whether specifically killing cells displaying any of these 17 in 2015 with a $20 million grant over five years to the University proteins will eliminate the latent reservoir. of California, San Francisco (UCSF). Researchers at the Institute have been laying the groundwork for a complex clinical study u Impact Grants of up to $2 million each over four years support employing a three-pronged approach to eradicating HIV. A the in-depth development of concepts already underpinned by therapeutic vaccine will be combined with an immune adjuvant—a preliminary data showing genuine potential for achieving a cure. drug often used to boost the efficacy of vaccines—that has been In September 2018, amfAR awarded grants totaling $828,000 to shown in clinical trials to have additional anti-HIV effects. The advance two critical areas of HIV cure research. Five grants are third component combines two broadly neutralizing antibodies, supporting a range of efforts to understand the mechanisms and the source of much optimism in the cure field for their ability not predictors of post-treatment control, whereby a small number of only to kill viruses that are produced by infected cells, but also to individuals are able to control their HIV after stopping treatment. direct the immune system to kill the cells producing those viruses. Three additional grantees are studying HIV-positive populations in low- and middle-income countries to look for differences in how u Investment Grants, awarded over a four-year period, are the persistent viral reservoir forms and changes over time. aimed at recruiting the experience and expertise of scientists from outside the field of HIV. Grantees may have expertise in u ARCHE, the amfAR Research Consortium on HIV Eradication, fields such as cancer, neuroscience, or inflammatory disease supports collaborative teams of scientists in the U.S. and around that can directly inform efforts to cure HIV. In February 2019, the world working on a range of HIV cure strategies. In September amfAR announced new funding to researchers using cutting- 2018, amfAR awarded $800,000 in new ARCHE funding to six teams of researchers developing an ambitious gene therapy-

1 based approach to curing HIV. The award launched a critical new u The Fellowships in Basic Biomedical Research phase in a study initiated in 2017. In a three-pronged attack on the support bright young scientists advancing innovative solutions to HIV reservoir, the researchers are employing broadly neutralizing HIV/AIDS. In September 2018, amfAR announced the recipient of antibodies, CAR stem cells—cells genetically reprogrammed the 2018 Mathilde Krim Fellowship in Basic Biomedical Research: to recognize and attack infected cells—and molecular scissors Dr. Yen-Ting Lai of the Vaccine Research Center/National targeting the virus. The grant was supported in part by the Bill and Institutes of Health in Bethesda, MD. The 2019 Krim fellows, Dr. Melinda Gates Foundation. Maolin Lu of Yale University in New Haven, CT, and Dr. Shaheed Abdulhaqq, of Oregon Health and Science University in Portland, The investigators are: Dr. Hildegard Büning of Hannover Medical OR, were announced in September 2019. Each fellow is awarded School, Germany; Dr. Keith Jerome of the University of Washington, approximately $150,000 over two years. Seattle; Dr. Hans-Peter Kiem of Fred Hutchinson Cancer Research Center, Seattle; Dr. Scott Kitchen of UCLA; Dr. Yasuhiro Takeuchi of University College London; Dr. Drew Weissman of University of Pennsylvania in Philadelphia; and Dr. Richard Wyatt of The Scripps Research Institute in La Jolla, CA.

In June 2019, amfAR awarded $1.16 million in ARCHE grants for a pair of innovative research studies pursuing different angles to attack HIV. Dr. Keith Jerome of the University of Washington, Seattle, was awarded $344,000 for a project that aims to advance a cost-effective in vivo gene therapy strategy for curing HIV in which gene-editing tools are injected directly into the patient using vectors that function like ‘Trojan horses.’

And Dr. Jonathan Li of Brigham and Women’s Hospital, Boston, was awarded $815,000 for a project studying post-treatment control of the virus. Dr. Li and his team are gathering and analyzing samples from a multinational cohort of post-treatment controllers Dr. Shaheed Abdulhaqq to investigate whether characteristics of the virus or immunologic responses predict control. Discovering what leads to post-treatment Published Research control in some people could help to achieve durable ART-free control in all people living with HIV. Research studies make the greatest impact on the HIV field and on the broader scientific community when they are published in scientific journals. In FY2019, 53 scientific publications resulted from amfAR-funded research.

The “London Patient”

In the March 2019 issue of Nature, researchers affiliated with amfAR’s IciStem consortium reported on the “London patient,” who may be only the second person to have been cured of HIV following a stem cell transplant. This case—along with the “Düsseldorf patient,” who may also have been cured—is providing critical new data to compare with the case of the “ patient,” the first known case of a cure.

A Family Trait

CCR5, the primary receptor enabling HIV to infect cells, is known for its role in the cure of the “Berlin patient” following a stem cell transplant with donor cells bearing a mutated CCR5 protein. In the April 2019 issue of eLIFE, Dr. Steven Deeks of UCSF and colleagues reported that people with a natural ability to control their HIV without ART had less CCR5 present on their cells than noncontrollers, and their cells were less permissive to HIV infection. Furthermore, natural resistance to HIV through reduced levels of CCR5 was shown to be inherited.

Dr. Yen-Ting Lai

2 Identifying a Biomarker for the ‘Active’ HIV Reservoir PUBLIC POLICY In the May 2019 issue of Pathogens and Immunity, Drs. Timothy Henrich and Peter Hunt, both at UCSF, reported on a potential biomarker of the “active reservoir”—persistent virus that is probably Informed by thorough research and analysis, amfAR is a highly first to re-seed infection when ART is stopped. Thinking on the respected advocate of rational and compassionate HIV/AIDS- nature of the reservoir is evolving to include not only latent, but also related public policy. The Foundation is engaged in efforts to active reservoir. Differentiating cells harboring active reservoir from secure necessary increases in funding for HIV/AIDS research and healthy, uninfected cells would be an important advance. global HIV/AIDS programs, expand access to treatment and care for marginalized populations, advocate harm reduction policies aimed at reducing the spread of HIV and hepatitis C (HCV) among HIV Cure Summit people who inject drugs, and protect the civil rights of all people In December 2018, amfAR held its fifth annual HIV Cure Summit at affected by or vulnerable to HIV/AIDS. UCSF, where the amfAR Institute for HIV Cure Research is based. Leading amfAR-funded cure researchers detailed their progress Ending the Domestic HIV Epidemic and discussed the scientific challenges that stand in the way of a cure. Dr. Rowena Johnston, amfAR vice president and director In 2019, President Trump announced a plan to end HIV of research, elucidated the two types of cure that researchers are transmissions in the U.S. by 2030, targeting geographic hotspots pursuing: eradication and post-treatment control. In eradication, an of infection. The Ending the HIV Epidemic (EHE) initiative aims individual completely clears HIV from his or her body, while in post- to reduce HIV infections by 75% in five years, and by 90% in treatment control some virus remains but the immune system can ten years. In 2019, amfAR launched a free interactive database control it without ART. Dr. Steven Deeks, a professor of medicine at (ehe.amfar.org) to help policymakers, public health officials, UCSF and a lead investigator at the amfAR Institute, explained the advocates, and other stakeholders understand the opportunities complex clinical study he is about to embark on. The Summit also and challenges across EHE jurisdictions. The EHE database featured a range of perspectives from members of the community includes demographic, policy, and service provider information, and advisory board for the amfAR Institute and other community leaders. epidemiological indicators. In 2018 the Trump administration proposed a rule change to the Title X National Family Planning Program, stating that health providers in the Title X program “may not perform, promote, refer for, or support abortion.” The stipulation is commonly known as the domestic gag rule. In February 2019, amfAR published Title X, the Domestic Gag Rule, and the HIV Response, an issue brief illustrating the benefits of the Title X program and potential impacts of the gag rule. Analysis from the report shows that, if implemented, the domestic gag rule could not only undermine women’s access to reproductive health services, but also impede access to HIV testing for low-income populations, threatening the national response to the HIV epidemic.

And in March 2019, amfAR published an issue brief titled Expanding Access to Pre-Exposure Prophylaxis (PrEP) for Adolescents and Young Adults: Models for Addressing Consent, (Left to right) Dr. Rowena Johnston, Clark Hawley, Cecilia Chung, Dr. Peter Confidentiality, and Payment Barriers. Ensuring that adolescents Hunt, and Socorro (Cori) Moreland and young adults at risk for HIV can access PrEP is a key step toward reducing the number of HIV diagnoses. Think Tanks

Consistent with amfAR’s commitment to investigate every avenue HIV and the Opioid Epidemic that may lead to a cure, the Foundation regularly hosts think tanks amfAR’s Opioid & Heath Indicators Database (opioid.amfar.org) is that bring together leading investigators in various fields. a free web platform designed to support lawmakers, communities, In March 2019, amfAR convened experts to discuss cutting-edge and advocates in making informed policy decisions about the approaches to curing HIV that amfAR could pursue through its gene opioid epidemic and its impact on HIV and hepatitis C. It provides therapy research initiative, ARCHE-GT. In May, members of amfAR’s local to national statistics using reliable data sources on new HIV IciStem consortium of European researchers that aims to replicate and hepatitis C infections, opioid use and overdose death rates, the case of “the Berlin patient” gathered for a think tank in Dublin, and the availability of services like drug treatment programs and Ireland. And in August, amfAR hosted a think tank in syringe exchange. on the CCR5 receptor as a target in cure research. The researchers In October 2018, amfAR published an analysis in Health Affairs discussed ways to use CCR5 to develop a more generalizable cure on the low percentage of substance use facilities that test for than one involving risky and costly stem cell transplants.

3 and colleagues presented findings from a survey used to track the impact of the Expanded Mexico City Policy on the operations and service delivery of organizations receiving assistance through PEPFAR. In 2017 the Mexico City Policy, or “global gag rule,” was reinstated and expanded to restrict non-U.S.-based or foreign NGOs from receiving American financial aid if they perform, counsel on, or refer for abortion, or advocate for its liberalization outside of limited exceptions.

In January 2019, amfAR published an issue brief reporting on disruptions in service provision due to the Expanded Mexico City Policy. Based on the survey described above, amfAR revealed that PEPFAR partners in 31 countries reported disruptions in service provision due to the policy. These findings have serious implications for reproductive health and the global HIV epidemic. amfAR subsequently produced a companion infographic titled PEPFAR Programming Disrupted by Expanded Mexico City Policy.

amfAR launched the PEPFAR Monitoring, Evaluation, and Reporting Database (mer.amfar.org) in December 2018. The database enables policymakers, public health officials, advocates, and other stakeholders to access a wide range of programmatic PEPFAR data and includes downloadable PDFs, maps, data visualizations, and district-level data. The new database complements amfAR’s existing PEPFAR database (copsdata.amfar.org), which highlights planned funding by program area, country, and organization for each year HIV or hepatitis C. published several articles that has been publicly released. The database is designed to help highlighting the bipartisan opioid bill passed by Congress that PEPFAR in its efforts to increase data transparency and participation linked to amfAR’s original Health Affairs analysis on the dearth of in the planning process. substance use treatment facilities that offer medication-assisted treatment (MAT) nationwide. In February 2019, amfAR, in conjunction with AVAC, published an issue brief titled New HIV Testing Strategies in PEPFAR COP19: Since uptake of treatment for substance use disorder and harm Rollout and Human Rights Concerns. The brief analyzes country reduction services at syringe services programs (SSPs) can reduce operational plan (COP) guidance for HIV testing and recommended the risk of HIV and hepatitis C acquisition, access to services is policies aimed at helping to find HIV-positive people who have critically important. In November 2018, amfAR published Getting to not been identified by other testing programs and linking them Services: Far, Far Away, an infographic showing how far Americans to treatment. must travel to substance use clinics offering MAT and SSPs. Nearly 30% of Americans live more than ten miles from a facility providing And in May, amfAR published a pair of infographics demonstrating medication-assisted treatment, and nearly 80% live more than ten the effectiveness of the Global Fund to Fight AIDS, Tuberculosis miles from an SSP. According to one study, people typically do not and Malaria: A Global Response to HIV Requires the Global Fund access SSPs if they are more than ten miles from where they live. and How the Global Fund Improves PEPFAR Investments. The Global Fund and PEPFAR are the world’s largest and most effective In August 2019, amfAR Senior Policy and Medical Advisor Dr. Susan investors in HIV treatment and prevention. Blumenthal penned an op-ed on ThriveGlobal on the need for a strategic plan for addressing the opioid epidemic in the same vein as the national strategy developed to address HIV. IAS 2019

amfAR’s Public Policy Office participated in the 10th International Advocating on the Global Stage AIDS Society Conference on HIV Science (IAS 2019) in Mexico City in July. In October 2018, amfAR published a first-of-its-kind analysis quantifying indirect costs charged by organizations implementing amfAR Vice President and Director of Public Policy Greg Millett the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR). joined Dr. Anthony Fauci, director of the National Institute of Allergy Examining data from 2007 to 2016, the study found that between and Infectious Diseases, at a press conference on “Translating $1.85 billion and $4.34 billion was spent on indirect costs. The study Progress Into Success to End the AIDS Epidemic.” The press was published in the peer-reviewed online journal PLOS One, and conference coincided with the release of a report with the same called for increased transparency in reporting indirect costs incurred name, coauthored by amfAR, AVAC, and Friends of the Global Fight by PEPFAR. Against AIDS, Tuberculosis and Malaria. The report shows places across the global north and south on track to end their respective At the biennial HIV Research for Prevention conference in Madrid, epidemics and the commonalities between them. also in October 2018, amfAR policy associate Jennifer Sherwood

4 Mr. Millett also spoke at a journalist roundtable sponsored by The TREAT Asia HIV Observational Database (TAHOD) gathers AVAC, and shared the stage at a separate meeting with World information to inform the development of more effective research Health Organization representatives and Ambassador Deborah and treatment programs and helps define treatment standards Birx, U.S. Global AIDS Coordinator, to debate the ethics of HIV specific to HIV/AIDS in Asia. The TAHOD-LITE database, an recency testing in PEPFAR programs. extension of TAHOD, contains data from over 37,000 HIV-positive patients across 10 TREAT Asia network sites and aims to increase the scope of adult data collection by gathering a subset of core variables from all HIV-infected patients who have sought care at TREAT ASIA selected TAHOD sites.

A Global Collaboration amfAR’s TREAT Asia (Therapeutics Research, Education, and AIDS Training in Asia) program is a network of hospitals, clinics, TREAT Asia manages the Asia-Pacific section of the International and research institutions working with civil society to ensure epidemiology Databases to Evaluate AIDS (IeDEA), a global the safe and effective delivery of treatments for HIV and its co- collaboration established by the U.S. National Institute of Allergy and infections to adults and children across the Asia-Pacific through Infectious Diseases. In FY2019, the IeDEA consortium completed research, education, and advocacy. The TREAT Asia Network STAY (Study of Transitioning Asian Youth), which documented the encompasses 21 adult and 20 pediatric sites throughout the experience of HIV-positive young adults transitioning from pediatric region, which collaborate on a variety of projects. TREAT Asia to adult care. scientists produced 38 publications in peer-reviewed medical journals in 2019. Improving Care for Children

The TREAT Asia Pediatric HIV Observational Database is a regional Gathering Critical Information pediatric HIV study set up by TREAT Asia in 2006. It was modeled TREAT Asia pioneered the region’s first adult observational on the adult database and includes data from more than 6,400 database for HIV/AIDS, which now includes anonymous data children and adolescents at 17 clinical sites in , , from nearly 10,000 patients at 21 clinical sites in 12 countries. , , , and .

5 Integrating HIV, Mental Health, and Implementation investigator, discussed the current state of the HIV epidemic in Asia, Science Research and highlighted priority issues for the regional response.

In May 2019, the U.S. National Institutes of Health awarded a five- In January 2019, TREAT Asia produced a fact sheet summarizing year, $1.4 million grant to TREAT Asia and Columbia University WHO guidelines (updated, July 2018) aimed at helping policymakers to establish an innovative platform for integrating HIV, mental and healthcare providers in low- and middle-income countries health, and implementation science research in the Asia-Pacific establish hepatitis C screening, care, and treatment programs. region. Co-led by Dr. Annette Sohn, amfAR vice president and In addition, TREAT Asia continued to publish lay-language articles director of TREAT Asia, and Dr. Milton Wainberg, professor of on HIV/AIDS research, policy, and community issues facing the clinical psychiatry at Columbia University and the New York State Asia-Pacific region. The articles and educational pieces appear in Psychiatric Institute, the CHIMERA program (Capacity development the TREAT Asia Report, a bimonthly e-newsletter, and on TREAT for HIV and mental health research in Asia) is nested within the Asia’s website, www.treatasia.org. IeDEA (see above) Asia-Pacific regional research network. CHIMERA will bring together stellar training faculty from academic centers and public health and development agencies, and will build on existing Conferences NIH-funded mental health research being conducted through At the 10th International AIDS Society Conference on HIV Science IeDEA Asia-Pacific. (IAS 2019) in Mexico City in July, TREAT Asia Director Dr. Annette

Sohn co-chaired a special session with former IAS President Dr. Aiding and Empowering Youth Chris Beyrer of Johns Hopkins University, called “Data leading Thirty percent of new HIV infections in the Asia-Pacific occurred in the way: Designing responses based on the numbers.” Dr. Sohn people aged 15–24 years in 2017. Continuing its commitment to was also a session co-chair at the International Workshop on HIV helping adolescents transition to adult care, in January 2019 TREAT Pediatrics, which convened immediately before the conference. Asia held a think tank on young adult cohort research. Giten Khwairakpam, TREAT Asia’s project manager for community and policy, co-chaired the 5th International HIV/Viral Hepatitis Co- In December 2018, TREAT Asia’s Youth ACATA—Asia Community Infection preconference. for AIDS Treatment and Advocacy—held a workshop in . Focused on models of service delivery for key populations, the workshop included site visits to community-based or key population-friendly HIV service providers in Bangkok.

Expanding Access to HIV Treatment

In 2018 the World Health Organization (WHO) recommended dolutegravir (DTG)-based regimens as the preferred first-line HIV treatment for adults and adolescents. But in the Asia-Pacific region, access to DTG-based regimens remains severely limited. To accelerate DTG scale-up in the region, TREAT Asia and the Clinton Health Access Initiative organized a workshop in Bangkok in March 2019 to help networks of people living with HIV and other treatment access advocates better understand issues around DTG access and use, and coordinate future advocacy efforts. And in April 2019, Giten Khwairakpam, TREAT Asia’s project manager for community and policy, led a training in Bangkok for regional community Dr. Annette Sohn at IAS 2019, Photo credit © International AIDS Society/ advocates around the use of DTG. Steve Forrest/Workers’ Photos

Advocating for Co-Infection Treatment Access

In June 2019, TREAT Asia held its annual regional advocacy meeting TREAT Asia was also well represented at the fourth Asia Pacific on hepatitis C, HIV, and tuberculosis treatment in Bangkok, with civil AIDS & Co-Infections Conference (APACC), held in June 2019 in society organizations, clinical care professionals, and intellectual . Several junior investigators and Ph.D. students affiliated property experts. During the year, TREAT Asia staff also presented with the TREAT Asia network gave oral and poster presentations at at several conferences on hepatitis C treatment access and the conference. partnered with civil society groups and funders on advocacy efforts. The TREAT Asia Annual Network Meeting was held in October 2018

in Bangkok, Thailand, where more than 120 adult and pediatric Publications investigators, donors, and program partners gathered to review TREAT Asia Director Dr. Annette Sohn co-authored an op-ed for progress, hear about regional HIV-related policy priorities, and plan Asia-Pacific Biotech News, titled “Asia-Pacific: Falling Behind in the for future initiatives. Fight Against HIV/AIDS.” The op-ed, coauthored by a Singaporean

6 THE GMT INITIATIVE

In order to focus on its core programs, amfAR is winding down its GMT Initiative, launched in 2007. The initiative was designed to support research teams and community-based partner organizations in evaluating interventions to reduce the spread and impact of HIV among , other men who have sex with men, and transgender individuals (collectively, GMT) in low- and middle- income countries.

In FY2019, amfAR continued to support its final two GMT Initiative projects. Dr. Chris Beyrer of Johns Hopkins University in Baltimore is leading a team of researchers and community-based services (in collaboration with the International HIV/AIDS Alliance Myanmar) in evaluating the effectiveness of promising interventions for GMT in Myanmar. The researchers are assessing the effectiveness of HIV self-testing done in the privacy of one’s home, point-of-care CD4 testing, and the use of “peer navigators” familiar with the local health system to help the newly diagnosed access HIV treatment and care.

In Bangkok, Dr. Nittaya Phanuphak and her team at the Thai Red Cross AIDS Research Centre aim to show how innovative technologies such as websites using online counseling and support can be utilized to increase rates of HIV testing and referrals to prevention and treatment programs. Working in collaboration with programs and activities. The websites attract a combined average Adam’s Love, a web-based health platform for GMT individuals, and of 36,000 visitors per month. amfAR also creates and distributes community organizations, the team is comparing the effectiveness reports, press releases, and updates on major HIV/AIDS issues of online services and support interventions with traditional clinic- and conducts public service advertising campaigns that have been based HIV services, and a hybrid model that combines elements of instrumental in educating policymakers, healthcare professionals, both strategies. people living with HIV/AIDS, and the public.

Public Policy

PUBLIC INFORMATION amfAR’s Public Information team works closely with the Public Policy Office (see above) to produce a wide range of issue briefs, facts sheets, infographics, and reports. In 2019 it also worked with amfAR disseminates information on important HIV-related research, an animation studio to produce a short film showcasing the features treatment, prevention, and policy issues for diverse audiences and functionality of amfAR’s Opioid & Health Indicators Database to increase awareness and knowledge of the pandemic. amfAR (opioid.amfar.org). publishes a wide range of educational materials, maintains an informative website, and engages respected public figures, HIV/ Social Media AIDS scientists, and policymakers in communicating the need for continued research to develop new methods of prevention, amfAR has vigorously expanded its presence in the social media treatment, and, ultimately, a cure for HIV. arena, reaching large numbers of people, including a younger demographic that is often less educated about HIV and the AIDS epidemic. The Foundation regularly adds content to its Educational Materials Facebook page, live tweets from events, and posts images, amfAR produces a range of periodicals in both print and electronic videos, news, and information on Instagram. amfAR has 73,000 formats, including its newsletter Innovations, published twice a year likes on Facebook, more than 43,000 Twitter followers, and and distributed to more than 40,000 people; the TREAT Asia Report, 164,000 Instagram followers. an email newsletter distributed six times a year to more than 4,000 readers in the international health community; and a monthly e-mail Media Outreach newsletter distributed to approximately 11,000 people. In FY2019, amfAR continued to work closely with the media to raise The Foundation’s websites—www.amfar.org and www. the profile of HIV/AIDS, both domestically and internationally, and curecountdown.org—feature news, interviews, and original articles to help ensure the accuracy of HIV-related press coverage. Articles covering HIV research, policy, the global epidemic, and amfAR and reports involving amfAR—many of which included interviews

7 with staff—were carried in numerous media outlets, including The amfAR is profoundly grateful for the continuing support of celebrities New York Times, WIRED, Science, The Washington Post, Bangkok from all over the world, including , Dame Shirley Bassey, Post, USA Today, U.S. News & World Report, People, Vox, Vogue, Matt Bomer, Zoe Saldana, Grace Jones, , , Vanity Fair, Essence, Bustle, The Advocate, POZ, CBS News, NBC Alan Cumming, Michelle Rodriguez, Karolina Kurkova, Alessandra News, ABC News, Fox News, NPR, Associated Press, and Reuters. Ambrosio, Caroline Vreeland, , Elsa Hosk, Karen Elson, , Victoria Justice, , Alexander

Celebrity Support Skarsgård, Pharrell Williams, Michelle Yeoh, Nicole Scherzinger, Charli XCX, Chris Tucker, Carine Roitfeld, Henry Golding, Eva amfAR’s public awareness efforts are greatly enhanced by the Longoria, Andie MacDowell, , Patricia Arquette, committed support of public figures who lend their voices and , Orlando Bloom, Ian Bohen, Adrien Brody, donate their time, talents, and resources to help advance the H.E.R., Tommy Hilfiger, Julian Lennon, , Coco Rocha, Foundation’s mission. Support of amfAR by prominent public figures , Christoph Waltz, Rebel Wilson, CeeLo Green, Joan began with the late Dame , amfAR’s Founding Smalls, and Rita Ora. International Chairman, and others have followed in her footsteps.

8 2019 RESEARCH IMPACT GRANTS: GAINING INSIGHTS INVESTMENT GRANTS: BRINGING FROM THE CLINIC BIOENGINEERS TO CURE HIV – GRANTS, FELLOWSHIPS PHASE III AND AWARDS Novel glycomic biomarkers predicting time to HIV rebound after treatment interruption Deciphering latency-associated sugar-code to Mohamed Abdel-Mohsen, PhD detect and eliminate latent reservoir The Wistar Institute Weiming Yang, PhD All projects listed below were awarded Philadelphia, PA Johns Hopkins University funding during the period October 1, 2018, $130,000 Baltimore, MD $800,000 through September 30, 2019. Immunological, genetic and virological analyses of HIV remission in the HEATHER cohort – the PITCH study arm John Frater, MD, PhD, FRCP MATHILDE KRIM FELLOWSHIPS IN amfAR Research Consortium on HIV University of Oxford BIOMEDICAL RESEARCH Eradication (ARCHE) Oxford, Oxfordshire, United Kingdom $299,342 Determination of HIV resistance mechanisms with ATI following allogeneic SCT with delta 32 entry inhibitors targeting the conserved receptor donor tissue Temporal phylogenetic characterization of binding site Ravindra Gupta, MD, PhD the latent HIV reservoir in a cohort of virally Yen-Ting Lai, PhD University of Cambridge suppressed Ugandans National Institutes of Health Cambridge, Cambridgeshire, UK Edward Nelson Kankaka, MBChB, MPH Bethesda, MD $45,000 Rakai Health Sciences Program $150,000 Kampala, Uganda Immune and viral determinants of HIV rebound $50,000 Developing a machine-learning-guided HIV Jonathan Li, MD, MMSc immunogen design to elicit cross-reactive Determinants of HIV rebound and remission The Brigham and Women’s Hospital, Inc. neutralizing antibody responses Jonathan Li, MD, MMSc Boston, MA Wen-Han Yu, PhD The Brigham and Women’s Hospital, Inc. $815,014 Ragon Institute of MGH, MIT and Harvard Boston, MA Charlestown, MA $100,000 $150,000 ARCHE – GENE THERAPY GRANTS Characterization of HIV infected women that maintain without HAART sustained indetectable amfAR Research Consortium on HIV Eradication – viral load following PMTCT MATHILDE KRIM FELLOWSHIP GRANTS Gene Therapy (ARCHE-GT): Preparation Phase Godwin Nchinda, PhD – PHASE II Hildegard Büning, PhD Chantal Biya International Reference Center Hannover Medical School for Research on the Prevention and Management The immunomodulatory role of plasma IgA upon Hannover, Lower Saxony, Germany HIV/AIDS Fc-mediated functions in HIV $472,728 Yaounde, Center Region, Cameroon Amy Chung, PhD $49,400 AAV transgene delivery in vivo in non-human University of Melbourne primates HIV persistence and antigen-specific immunity: Melbourne, Victoria, Keith Jerome, MD, PhD the HIV hygiene hypothesis $50,000 University of Washington Reena Rajasuriar, PhD Seattle, WA University of Malaya $344,332 Kuala Lumpur, Malaysia MEETINGS AND CONFERENCES $49,659 ARCHE Gene Therapy Phase 2: Using LNPs to 9th International Workshop on HIV Persistence deliver gene therapy to cure HIV HIV persistence in lymph nodes in the face of ART During Therapy Drew Weissman, MD, PhD in TB-infected individuals Alain Lafeuillade, MD, PhD University of Pennsylvania Alex Sigal, PhD University of Massachusetts Medical School Philadelphia, PA Africa Health Research Institute (AHRI) Worcester, MA $327,272 Durban, KwaZulu-Natal, South Africa $20,000 $50,000 Conference on Cell & Gene Therapy for HIV Cure Mechanistic and empirical modeling of viral Keith Jerome, MD, PhD rebound to identify predictors of post-treatment Fred Hutchinson Cancer Research Center control Seattle, WA Rui Wang, PhD $10,000 Harvard Pilgrim Health Care Institute Wellesley, MA $99,810

79 AUSTRALIA Melbourne Sexual Health Centre 2019 TREAT ASIA Carlton GRANTS AND AWARDS University of New South Wales Richard Teague, MBBS (Monash Uni), FRACGP, Sydney FRAChSHM Matthew G. Law, PhD $5,8501 All projects listed below were awarded IeDEA Asia-Pacific Research Collaboration: TREAT Asia HIV Observational Database & Monash Health - Clayton funding during the period October 1, 2018, Australia HIV Observational Database Clayton through September 30, 2019. $302,4411 Ian Woolley, MBBS, FRACP $7,5001 IeDEA Asia-Pacific Research Collaboration: 1Supported by National Institutes of Health federal TREAT Asia Pediatric HIV Observational Database D.A. Ellis Pty Ltd Coffs Harbour award number U01AI069907 with funds from $186,3641 David Ellis, MBBS the National Institute of Allergy and Infectious IeDEA Asia-Pacific Research Collaboration: $525 Diseases, the Eunice Kennedy Shriver National Cancer Studies East Sydney Doctors Institute of Child Health and Human Development, $69,5201 Darlinghurst the National Cancer Institute, the National Institute David Baker, MB, ChB, Dip Med (Sexual Health), on Drug Abuse, the National Institute of Diabetes DCH and Digestive and Kidney Diseases, the National AUSTRALIAN HIV RESEARCH $6,3001 COLLABORATION (AHOD) SITES Heart, Lung and Blood Institute, National Institute St. Vincent’s Hospital Sydney Limited on Alcohol Abuse and Alcoholism, and the O’Brien Street Practice Darlinghurst Fogarty International Center Adelaide Andrew Carr, MD William Donohue, MBBS $7,5001 2Supported by National Institutes of Health federal $1,500 Taylor Square Private Clinic award number R01HD073972 funded by the Sexual Health and HIV Service In Metro North Darlinghurst Eunice Kennedy Shriver National Institute of Child Brisbane Robert Finlayson, MBBS (Syd), Di Health and Human Development Diane Rowling, MBBS, MTH, F(PHM), RACP, $7,4251 FACSHM 3Supported by National Institutes of Health federal $7,5001 Northern Territory Dept of Health & Community Services, Sexual Health & Blood Borne Virus award number R21HD89859 funded by the Eunice Cairns Sexual Health Service Program Kennedy Shriver National Institute of Child Health Cairns Darwin and Human Development Darren Russell, MD Manoji Gunathilake, MBBS, MD, FAChSHM $7,5001 $2,025 4Supported by National Institutes of Health federal award number D43TW011302 funded by the RPA Sexual Health Clinic Gladstone Road Medical Centre Camperdown Highgate Hill Fogarty International Center and the National David Templeton, PhD David Orth, MBBS, DipVen Institute of Mental Health $7,5001 $6,0001 5Supported with funds provided by Life Ball

10 Nepean Blue Mountains Local Health District, Blue Cipto Mangunkusumo General Hospital Mountains Sexual Health and HIV Clinic Jakarta Katoomba Beijing Ditan Hospital Nia Kurniati, MD Eva Jackson, MBBS, FAChSHM Beijing TREAT Asia Pediatric HIV Observational Database $2,100 Fujie Zhang, MD, MSPH, PhD (TApHOD) Site Study on pregnancy and birth outcomes among $7,5001 Nepean Blue Mountains Local Health District, women living with HIV in Asia Nepean Sexual Health Clinic $8,0001 Evy Yunihastuti, MD, PhD Kingswood TREAT Asia HIV Observational Database (TAHOD) Eva Jackson, MBBS, FAChSHM TREAT Asia HIV Observational Database (TAHOD) including NCD Data $1,950 $20,8001 $23,1921 Sexual Health and AIDS Services (SHAIDS) Queen Elizabeth Hospital Lismore Hong Kong David Smith, MBBS, DipVen, FAChSHM, GrapDip, Man Po Lee, MBBS TAHOD Low Intensity Transfer (TAHOD LITE) BA National Center for Global Health and Medicine 1 $7,9001 $7,500 Shinjuku Victorian HIV Service, Infectious Diseases TREAT Asia HIV Observational Database (TAHOD) Junko Tanuma, MD, PhD Department, The Alfred Hospital including NCD Data Study on pregnancy and birth outcomes among Melbourne $22,8801 women living with HIV in Asia 1 Jennifer Hoy, MBBS $5,000 1 $7,500 TREAT Asia HIV Observational Database (TAHOD) INDIA 1 Sunshine Coast Hospital and Health Service $16,640 Nambour West The Voluntary Health Services David Sowden, MBBS Chennai $7,5001 Nagalingeswaran Kumarasamy, MD, MBBS, PhD MALAWI TREAT Asia HIV Observational Database (TAHOD) Northside Clinic (Vic) Pty Ltd including NCD Data Lighthouse Trust North Fitzroy $46,4881 (funding for project years 13 & 14 Lilongwe Richard Moore, MBBS awarded in 2019) Sam Phiri, PhD $7,5001 Global fRAmework for Data Collection Used for TREAT Asia Pediatric HIV Observational Database Adolescent HIV Transition Evaluation (GRADUATE) Royal Perth Hospital (TApHOD) Site $5,3503 Perth $7,500 (project year 13); $7,5001 (project year 14) David Nolan, MBBS, FRACP, PhD $6,0001 BJ Medical College & Sassoon General Hospitals Pune MALAYSIA Prahran Market Clinic Pty Ltd Aarti Kinikar, MD, DCH; DNB; MRCP Pediatrics UK Prahran Hospital Raja Perempuan Zainab II TREAT Asia Pediatric HIV Observational Database Kota Bharu Norman Roth, MBBS, FAChSHM (TApHOD) Site $7,5001 Nik Khairulddin Nik Yusoff, MD $7,5001 TREAT Asia Pediatric HIV Observational Database Holdsworth House Medical Practice (TApHOD) Site Shashikala Sangle, MD 5 Sydney TREAT Asia HIV Observational Database (TAHOD) $7,500 Mark Bloch, MD including NCD Data $7,5001 Hospital Likas $22,0481 Kota Kinabalu Sydney Sexual Health Centre, Sydney Hospital Institute of Infectious Diseases Fong Siew Moy, MBBS Sydney Pune TREAT Asia Pediatric HIV Observational Database Rick Varma, MBBS, MRCP (TApHOD) Site 1 Sanjay Pujari, MD, AAHIVS, MBBS 5 $6,900 Substance use, Stigma, Depression and Disability $7,500 Clinic 468, HNE Sexual Health, Hunter New among Adults with HIV in Asia (S2D2) Pilot Study Pediatric Institute, Hospital Kuala Lumpur England Local Health District $10,648 Kuala Lumpur Tamworth NEMSC TAHOD Low Intensity Transfer (TAHOD LITE) Thahira Mohamed, MBBS Nathan Ryder, MD $9,600 TREAT Asia Pediatric HIV Observational Database $1,500 (TApHOD) Site TREAT Asia HIV Observational Database (TAHOD) $7,5005 Illawarra Shoalhaven Local Health District including NCD Data Warrawong $22,3601 University of Malaya Medical Center Katherine Brown, MD Kuala Lumpur $1,650 Raja Iskandar Shah Raja Azwa, MBBS Substance use, Stigma, Depression and Disability INDONESIA among Adults with HIV in Asia (S2D2) Pilot Study CAMBODIA Sanglah Hospital, Udayana University School of $10,648 Medicine TREAT Asia HIV Observational Database (TAHOD) National Center for HIV/AIDS, Dermatology Denpasar including NCD Data & STDS / Cambodia National Institute of Tuti Parwati Merati, MD, PhD $22,3601 Public Health TAHOD Low Intensity Transfer (TAHOD LITE) Phnom Penh $8,4001 Sungai Buloh Hospital Ly Penh Sun, MD, MSc Sungai Buloh TAHOD Low Intensity Transfer (TAHOD LITE) TREAT Asia HIV Observational Database (TAHOD) Yasmin Mohamed Gani, MD $9,0001 including NCD Data TREAT Asia HIV Observational Database (TAHOD) $22,8801 including NCD Data TREAT Asia HIV Observational Database (TAHOD) $22,8801 $20,8001 Ketut Dewi Kumara Wati, MD TREAT Asia Pediatric HIV Observational Database TREAT Asia Pediatric HIV Observational Database (TApHOD) Site (TApHOD) Site $7,5001 $25,0001

911 Wits Health Consortium (Pty) Ltd TREAT Asia HIV Observational Database (TAHOD) Parktown, JHB including NCD Data Asian Foundation for Tropical Medicine, Inc. Karl Technau, MBBCh, MSc (Med) $24,9601 Muntinlupa City Global fRAmework for Data Collection Used for Rossana Ditangco, MD Adolescent HIV Transition Evaluation (GRADUATE) Substance use, Stigma, Depression and Disability $7,6473 among Adults with HIV in Asia (S2D2) Pilot Study THAILAND $10,648 Chulalongkorn University TREAT Asia HIV Observational Database (TAHOD) Bangkok including NCD Data Thanyawee Puthanakit, MD $22,360 Yonsei University College of Medicine Change of bone mineral density among perinatally Seoul HIV-infected adolescents after stopping calcium Jun Yong Choi, MD, PhD and vitamin D (CAL-D2) Study on pregnancy and birth outcomes among $4,3701 women living with HIV in Asia $1,2001 TREAT Asia Pediatric HIV Observational Database Tan Tock Seng Hospital (TApHOD) Site Singapore Substance use, Stigma, Depression and Disability $15,0001 Oon Tek Ng, MBBS, MRCP, MMed, MPH among Adults with HIV in Asia (S2D2) Pilot Study TREAT Asia HIV Observational Database (TAHOD) $10,648 HIV-NAT / Thai Red Cross AIDS Research Centre $18,2001 Bangkok TAHOD Low Intensity Transfer (TAHOD LITE) Anchalee Avihingsanon, MD, PhD $6,4001 Substance use, Stigma, Depression and Disability SOUTH AFRICA among Adults with HIV in Asia (S2D2) Pilot Study TREAT Asia HIV Observational Database (TAHOD) $10,648 University of Cape Town including NCD Data $17,6801 TAHOD Low Intensity Transfer (TAHOD LITE) Mowbray 1 Mary-Ann Davies, MBChB, MMed, FCPHM $8,400 Global fRAmework for Data Collection Used for TREAT Asia HIV Observational Database (TAHOD) Adolescent HIV Transition Evaluation (GRADUATE) including NCD Data $64,3513 1 Taipei Veterans General Hospital $24,440 Global fRAmework for Data Collection Used for Taipei City Adolescent HIV Transition Evaluation (GRADUATE) Yu-Jiun Chan, MD Supplement TAHOD Low Intensity Transfer (TAHOD LITE) $3,0003 $6,4001 (year 1); $69001 (year 2)

1012 Mahidol University by Faculty of Medicine Siriraj TREAT Asia Pediatric HIV Observational Database Hospital (TApHOD) Site 2019 PUBLIC POLICY Bangkok $7,5001 AWARDS Kulkanya Chokephaibulkit, MD Global fRAmework for Data Collection Used for Purple Haze Company Limited Adolescent HIV Transition Evaluation (GRADUATE) Muang The projects listed below were awarded $2,660 Tarandeep Anand The impact of online interventions on the HIV funding during the period October 1, 2018, Human Papillomavirus Infection in Perinatally HIV- prevention/treatment cascade among MSM and through September 30, 2019. infected Adolescents in Asia (Supplement) TG Individuals $1,0002 $30,0001 TREAT Asia Pediatric HIV Observational Database Community monitoring to influence and monitor (TApHOD) Site PEPFAR country programs $7,5001 USA Project Director: Jamila Headley Health GAP (Global Access Project) Ramathibodi Hospital, Mahidol University Johns Hopkins University Brooklyn, New York Bangkok Baltimore $47,995 Sasisopin Kiertiburanakul, MD, MHS Vidya Mave, MD, MPH Epidemiology of HIV/AIDS and associated Towards evidence-based programming: data on TAHOD Low Intensity Transfer (TAHOD LITE) sex workers’ programming in $10,4001 comorbidities in a public antiretroviral treatment (ART) clinic in Pune, India (Supplement) Project Director: Josephine Achieng TREAT Asia HIV Observational Database (TAHOD) $45,8971 Bar Hostess Empowerment and Support including NCD Data Programme (BHESP) $22,8801 Massachusetts General Hospital Nairobi, Kenya Boston $30,000 Thai Red Cross AIDS Research Centre Andrea Ciaranello, MD, MPH Bangkok Estimating the magnitude of the pediatric and Nittaya Phanuphak-Pungpapong, MD, PhD adolescent HIV epidemic in Thailand Amphetamine-type stimulant use, HIV incidence, $30,000 and ART adherence among Thai MSM and transgender women Columbia University 2019 COMMUNITY $100,8651 New York Milton Wainberg, MD OUTREACH AWARDS Anal HPV and risk for anal high-grade squamous Capacity development for HIV and mental health intraepithelial lesion among Thai MSM with acute research in Asia (CHIMERA) The projects listed below were awarded HIV infection $46,7634 $97,9451 funding during the period October 1, 2018, through September 30, 2019. Chiang Mai University - Research Institute for Health Sciences VIETNAM Chiang Mai Bach Mai Hospital Community Outreach Award: Black AIDS Institute Romanee Chaiwarith, MD, MHS Hanoi TREAT Asia HIV Observational Database (TAHOD) PrEP Outreach Programs Do Duy Cuong, MD, PhD Project Director: Phill Wilson including NCD Data TAHOD Low Intensity Transfer (TAHOD LITE) 1 Black AIDS Institute $23,920 1 $8,400 , California Tavitiya Sudjaritruk, MD, ScM TREAT Asia HIV Observational Database (TAHOD) $25,000 Change of bone mineral density among perinatally including NCD Data Community Outreach Award: Pour Les Femmes HIV-infected adolescents after stopping calcium $22,3601 and vitamin D (CAL-D2) Project Director: Shawn Jensen $5,7231 National Hospital of Pediatrics Schwab Charitable Fund Hanoi Orlando, Florida TREAT Asia Pediatric HIV Observational Database Nguyen Van Lam, MD, MSc $45,000 (TApHOD) Site TREAT Asia Pediatric HIV Observational Database 1 $15,000 (TApHOD) Site 1 Chiangrai Prachanukroh Hospital $20,000 Chiang Rai National Hospital of Tropical Diseases Suwimon Khusuwan, MD Hanoi TAHOD Low Intensity Transfer (TAHOD LITE) Nguyen Van Kinh, MD, PhD 1 $9,650 TAHOD Low Intensity Transfer (TAHOD LITE) TREAT Asia HIV Observational Database (TAHOD) $8,400 including NCD Data TREAT Asia HIV Observational Database (TAHOD) 1 $23,400 including NCD Data 1 Pradthana Ounchanum, MD $22,360 Global fRAmework for Data Collection Used for Children’s Hospital 1 Adolescent HIV Transition Evaluation (GRADUATE) Ho Chi Minh City $2,660 Truong Huu Khanh, MD You won’t be lost if we LINE: A quality TREAT Asia Pediatric HIV Observational Database improvement program to address lost to follow-up (TApHOD) Site 1 for HIV+ adolescents $20,000 $6,500 Children’s Hospital 2 Srinagarind Hospital, Khon Kaen University Ho Chi Minh City Khon Kaen Do Chau Viet, MD Pagakrong Lumbiganon, MD TREAT Asia Pediatric HIV Observational Database Global fRAmework for Data Collection Used for (TApHOD) Site 5 Adolescent HIV Transition Evaluation (GRADUATE) $20,000 $2,660

1113 12 FINANCIAL HIGHLIGHTS For the year ended September 30, 2019

Public Support and Revenue Public support $ 4,308,007 Special events 16,680,645 Planned giving 2,156,596 Government funding 6,017,798 Investment income and other revenue 2,552,030 Total public support and revenue $ 31,715,076

Expenses Research $ 15,365,954 TREAT Asia 4,670,067 GMT Initiative 268,329 Public Policy 2,049,054 Public Information 4,098,005 Total program services $ 26,451,409

Fundraising 5,884,444 Management and general 2,445,341 Total supporting services $ 8,329,785

Total expenses $ 34,781,194

Change in net assets (3,066,118) Net assets, beginning of year 52,550,679

Net assets, end of year $ 49,484,561

STATEMENT OF FINANCIAL POSITION

Assets Cash and investments $ 51,009,360 Pledges and receivables, net 7,207,120 Prepaid expenses and other assets 3,139,811 Furniture, equipment, and leasehold improvements, net 2,800,812 Total Assets $ 64,157,103

Liabilities Accounts payable and accrued expenses $ 2,769,299 Grants and fellowships payable, net 2,086,068 Deferred support and refundable advances 7,947,789 Other long-term liabilities 1,869,386 Total liabilities $ 14,672,542

Total net assets 49,484,561

Total liabilities and net assets $ 64,157,103

1315 EXPENSES

Fundraising $ 5,884,444 Management and general 2,445,341 Program 26,451,409

Total $ 34,781,194

PROGRAM EXPENSES

Research $ 15,365,954 TREAT Asia 4,670,067 GMT Initiative 268,329 Public Policy 2,049,054 Public Information 4,098,005

Total $ 26,451,409

1416 TRUSTEE EMERITUS BOARD OF TRUSTEES Alberto Bosque, Ph.D.* Fiscal year 2019 Arthur J. Ammann, M.D. Assistant Professor President, Global Strategies for HIV Prevention Department of Microbiology, Immunology, Clinical Professor of Pediatrics and Tropical Medicine Chairman of the Board University of California, San Francisco The George Washington University William H. Roedy San Francisco, CA Chairman, MTV International (retired) Jason Brenchley, Ph.D.* London Senior Investigator United Kingdom IN MEMORIAM Immunopathogenesis Section National Institute of Allergy and Vice Chairman Mathilde Krim, Ph.D. Infectious Diseases Cindy Rachofsky Founding Chairman National Institutes of Health Philanthropist Dallas, Texas Dame Elizabeth Taylor Dennis R. Burton, Ph.D. Founding International Chairman Professor Treasurer Department of Immunology Raymond F. Schinazi, Ph.D., D.Sc. Sheldon W. Andelson, Esq. The Scripps Research Institute Frances Winship Walters Professor Arnold W. Klein, M.D. Department of Pediatrics Mrs. Albert D. Lasker Salvatore T. Butera, D.V.M., Ph.D. Emory University School of Medicine Jonathan M. Mann, M.D., M.P.H. Chief Science Officer Atlanta, GA Maxine Mesinger Scripps CHAVI-ID Pauline Phillips The Scripps Research Institute Secretary Natasha Richardson Arlen H. Andelson Allan Rosenfield, M.D. Senior Partner (retired) Edward Campbell, Ph.D. Peter Scott, Esq. Assistant Professor Andelson & Andelson Wallace Sheft, C.P.A. Los Angeles, CA Department of Microbiology and Immunology Tom Stoddard School of Medicine Joel D. Weisman, D.O. Loyola University at Chicago

TRUSTEES Alex Carballo-Dieguez, Ph.D. SPECIAL APPOINTMENT Co-Director and Senior Research Scientist David Bohnett HIV Center for Clinical and Behavioral Studies Chairman Global Fundraising Chairman New York State Psychiatric Institute David Bohnett Foundation Milutin Gatsby Columbia University Beverly Hills, CA Amy Chung, Ph.D.* Jonathan S. Canno Laboratory Head New York, NY amfAR AMBASSADORS University of Melbourne Jay Ellis Cheyenne Jackson David B. Clifford, M.D. Jay Ellis Foundation Janet Jackson Los Angeles, CA Professor Milla Jovovich Department of Neurology Aileen Getty Washington University School of Medicine Founder and President Michelle Yeoh The Aileen Getty Foundation C. Budd Colby, Ph.D. Reno, NV Principal Colby Biomedical Ventures T. Ryan Greenawalt Managing Director Grant Colfax, M.D. Ramirez & Co. SCIENTIFIC ADVISORY Director Los Angeles, CA COMMITTEE Marin Health and Human Services Michael Klingensmith San Rafael, California Publisher and CEO Star Tribune Media Company *Adjunct Member Deborah Jean Cotton, M.D., M.P.H. Star Tribune Building Professor of Medicine Minneapolis, MN Mohamed Abdel-Mohsen, Ph.D.* Boston University School of Medicine Assistant Professor Edward L. Milstein Vaccine & Immunotherapy Center Bryan R. Cullen, Ph.D., D.Sc. Co-Chairman The Wistar Institute James B. Duke Professor Milstein Brothers Capital Partners Department of Molecular Genetics and New York, NY Maria Luisa Alcaide, M.D.* Microbiology Associate Professor of Clinical Infectious Diseases Director, Duke University Center for Virology Alan D. Schwartz Miller School of Medicine Duke University Medical Center Executive Chairman University of Miami Guggenheim Partners, LLC Susanna Cunningham-Rundles, Ph.D. New York, NY Galit Alter, Ph.D.* Professor Emerita of Research Immunology Mario Stevenson, Ph.D. Professor of Medicine Department of Pediatrics Professor of Medicine Harvard Medical School Weill Cornell Medical College Chief, Division of Infectious Diseases Ragon Institute of MGH, MIT and Harvard University of Miami Richard Thomas D’Aquila, M.D. Leonard M. Miller School of Medicine Jintanat Ananworanich, M.D., Ph.D. The Howard Taylor Ricketts Professor of Medicine Miami, FL Associate Director for Therapeutics Research Division of Infectious Diseases US Military HIV Research Program Director, Northwestern HIV Translational Phill Wilson Research Center Founder and CEO, Black AIDS Institute (retired) Judith Auerbach, Ph.D.* Feinberg School of Medicine Los Angeles, CA Professor of Medicine Northwestern University School of Medicine University of California, San Francisco

1517 Sara Gianella Weibel, M.D.* Scott Kitchen, Ph.D. Bruno De Geest, Ph.D. Assistant Professor of Medicine Assistant Professor of Medicine Chemical Engineer CFAR - Center for AIDS Research Division of Hematology and Oncology Laboratory of Pharmaceutical Technology Department of Medicine, Division of David Geffen School of Medicine Ghent University Hospital Infectious Diseases University of California, Los Angeles University of California, San Diego Sherry Deren, Ph.D. Richard Kornbluth, M.D., Ph.D. Co-Director Nancy L. Haigwood, Ph.D. President and Chief Scientific Officer Center for Drug Use and HIV Research Director and Senior Scientist Multimeric Biotherapeutics, Inc. New York University College of Nursing Division of Pathobiology and Immunology Oregon National Primate Research Center Richard A. Koup, M.D. Roger Detels, M.D., M.S. Oregon Health and Science University Deputy Director, Vaccine Research Center Professor of Epidemiology Chief, Immunology Laboratory School of Public Health Andrew Henderson, Ph.D.* National Institute of Allergy and University of California, Los Angeles Associate Professor Infectious Diseases School of Medicine National Institutes of Health Carl W. Dieffenbach, Ph.D. Boston University Director Nathaniel R. Landau, Ph.D. Division of AIDS (DAIDS) Alon Herschhorn, Ph.D.* Professor National Institute of Allergy and Assistant Professor of Medicine Department of Microbiology Infectious Diseases Division of Infectious Diseases and International New York University School of Medicine National Institutes of Health Medicine University of Minnesota Alan L. Landay, Ph.D. Ivan D’Orso, Ph.D.* Professor and Chairman Associate Professor Charles H. Hinkin, Ph.D. Department of Immunology and Microbiology Department of Microbiology Professor Rush-Presbyterian-St. Luke’s Medical Center University of Texas Southwestern Department of Psychiatry and Biobehavioral Sciences Michael Lederman, M.D. Daniel C. Douek, M.D., Ph.D. David Geffen School of Medicine Scott R. Inkley Professor of Medicine Chief, Human Immunology Section University of California, Los Angeles Associate Director, Center for AIDS Research Vaccine Research Center Case Western Reserve University National Institute of Allergy and David Ho, M.D. Infectious Diseases Scientific Director, Chief Executive Officer Tun-Hou Lee, D.Sc. National Institutes of Health Aaron Diamond AIDS Research Center Professor of Virology, Emeritus Department of Immunology and Infectious D. Peter Drotman, M.D., M.P.H. Ya-Chi Ho, M.D., Ph.D.* Diseases Editor-in-Chief Assistant Professor of Microbial Pathogenesis and Harvard School of Public Health Emerging Infectious Diseases Medicine Centers for Disease Control and Prevention Microbial Pathogenesis Michael J. Leibowitz, M.D., Ph.D. Yale University Professor, Medical Microbiology and Immunology Anke A. Ehrhardt, Ph.D. University of California, Davis Director Thomas J. Hope, Ph.D. Division of Gender, Sexuality, & Health Professor Robert J. Levine, M.D. Program for the Study of LGBT Health Department of Cell and Molecular Biology Professor of Medicine NYS Psychiatric Institute/Columbia University Feinberg School of Medicine Center for Interdisciplinary Research on AIDS Northwestern University Yale University Homayoon Farzadegan, Ph.D. Professor Shiu-Lok Hu, Ph.D. Judy Lieberman, M.D., Ph.D. Department of Epidemiology Professor Senior Investigator Johns Hopkins Bloomberg School of School of Pharmacy Immune Disease Institute Public Health University of Washington Professor of Pediatrics Harvard Medical School Dianne M. Finkelstein, Ph.D. Moses Joloba, M.B.Ch.B., M.S., Ph.D.* Professor of Biostatistics Associate Professor Manuel Llano, M.D., Ph.D.* Harvard School of Public Health College of Health Sciences, Department of Assistant Professor Director of the Cancer Center Biostatics Medical Microbiology University of Texas at El Paso Massachusetts General Hospital Makerere University School of Medicine H. Kim Lyerly, M.D. Andrés Finzi, Ph.D.* Case Western Reserve University Professor in Surgery, Immunology, Pathology Associate Professor George Barth Geller Chair of Cancer Research Department of Microbiology and Immunology R. Brad Jones, Ph.D.* Director of the Center of Applied Therapeutics Université de Montréal, Centre de Recherche Assistant Professor of Immunology in Medicine Duke Cancer Institute du CHUM Graduate School of Medical Sciences Duke University Medical Center Weill Medical College of Cornell University Gerald Herbert Friedland, M.D. Frank Maldarelli, M.D., Ph.D. Professor and Director Edward Kankaka, M.B.Ch.B., M.P.H.* Investigator AIDS Care Program Rakai Health Sciences Program HIV DRP Host-Virus Interaction Branch Department of Internal Medicine National Cancer Institute Yale School of Medicine Jonathan Karn, Ph.D.* National Institutes of Health Director Howard E. Gendelman, M.D. Center for AIDS Research David M. Margolis, M.D. Professor and Chair, Department of Pharmacology Case Western Reserve University Professor of Medicine, Microbiology and and Experimental Neuroscience Immunology, and Epidemiology Margaret R. Larson Professor of Internal Medicine Vineet KewalRamani, Ph.D. School of Medicine and Infectious Diseases Chief, Model Development Section University of North Carolina at Chapel Hill Director, Center for Neurodegenerative Disorders HIV Drug Resistance Program University of Nebraska Medical Center National Cancer Institute Martin H. Markowitz, M.D. National Institutes of Health Professor and Clinical Director Aaron Diamond AIDS Research Center

1618 Kenneth Hugh Mayer, M.D. Nadia Roan, Ph.D.* Lydie Trautmann, Eng.D., Ph.D.* Infectious Disease Attending & Director of HIV Associate Professor Chief Prevention Research Department of Urology Cellular Immunology Section Beth Israel Deaconess Medical Center University of California, San Francisco U.S. Military HIV Research Program Professor of Medicine Harvard Medical School Melissa Robbiani, Ph.D. Barbara Visscher, M.D., Dr.P.H. Medical Research Director, Co-Chair Senior Scientist and Director of Biomedical HIV Professor of Epidemiology The Fenway Institute/Fenway Health Research University of California, Los Angeles Center for Biomedical Research Joseph M. McCune, M.D., Ph.D. Population Council David Vlahov, Ph.D., R.N. Professor of Medicine Professor of Nursing, Department of Medicine Ruth M. Ruprecht, M.D., Ph.D. Epidemiology, and Biostatistics University of California, San Francisco Scientist, Department of Virology and Immunology University of California, San Francisco Southwest National Primate Research Center Donna Mildvan, M.D. Director, Texas Biomed AIDS Research Program David J. Volsky, Ph.D. Chief, Division of Infectious Diseases Texas Biomedical Research Institute Professor of Medicine and Pathology Department of Medicine Icahn School of Medicine at Mount Sinai Beth Israel Medical Center Joshua Schiffer, M.D.* Director of Molecular Virology Laboratory Associate Member Department of Medicine Godwin Nchinda, Ph.D.* Vaccine and Infectious Disease Division Mount Sinai St. Luke’s and Roosevelt Hospitals Professor Associate Member Senior Immunlologist Clinical Research Division Misaki Wayengera, M.B.Ch.B., M.Sc. Head of Vaccinology/Biobanking laboratory Fred Hutchinson Cancer Research Center Immunology, Ph.D.* Deputy Director General CIRCB Department of Pathology Chantal Biya International Reference Center for Frederick A. Schmitt, Ph.D. College of Health Sciences Research on the Prevention and Management Professor Makerere University of HIV/AIDS Departments of Neurology, Psychiatry, and Psychology and Behavioral Science Steven S. Witkin, Ph.D. Jay A. Nelson, Ph.D. Sanders Brown Center on Aging Professor of Immunology Professor and Director University of Kentucky Department of Obstetrics and Gynecology Vaccine and Gene Therapy Institute Weill Cornell Medical College Oregon Health and Science University Gerald Schochetman, Ph.D. Senior Director Peter R. Wolfe, M.D. Nancy Padian, Ph.D., M.P.H. Diagnostics Research Associate Clinical Professor Adjunct Professor of Epidemiology Abbott Laboratories David Geffen School of Medicine School of Public Health University of California, Los Angeles University of California, Berkeley Alex Sigal, Ph.D.* Sub-Investigator Group Leader, Max Planck Institute for Ruane Clinical Research Savita Pahwa, M.D. Infection Biology Professor of Microbiology and Immunology Africa Health Research Institute (AHRI) Kim Woodrow, Ph.D.* Professor in Pediatrics and Medicine Associate Professor Director of the Miami Center for AIDS Research Viviana Simon, M.D., Ph.D.* Department of Bioengineering University of Miami Leonard M. Miller School of Professor University of Washington Medicine Department of Microbiology Department of Medicine, Infectious Diseases Richard T. Wyatt, Ph.D. Tristram G. Parslow, M.D., Ph.D. Icahn School of Medicine at Mount Sinai Professor of Immunology William Patterson Timmie Professor and Chair IAVI Center for Neutralizing Antibodies Department of Pathology and Laboratory Gail Skowron, M.D. The Scripps Research Institute Medicine Professor of Medicine Emory University School of Medicine Boston University School of Medicine

Matija Peterlin, M.D. Leonidas Stamatatos, Ph.D. Professor of Medicine, Microbiology Member and Immunology Fred Hutchinson Cancer Research Center PROGRAM ADVISORY Department of Medicine Vaccine and Infectious Disease Division COUNCIL University of California, San Francisco Immunology and Vaccine Development Program

Lynn Pulliam, Ph.D. Spyridon Stavrou, Ph.D.* Professor Assistant Professor Mervyn F. Silverman, M.D., M.P.H. (Chairman) Department of Laboratory Medicine and Medicine Department of Microbiology and Immunology President University of California, San Francisco Jacobs School of Medicine & Biomedical Mervyn F. Silverman Associates Veterans Affairs Medical Center Sciences Crockett, CA State University of New York at Buffalo Reena Rajasuriar, Ph.D.* Judith D. Auerbach, Ph.D. Pharmacy Lecturer Kathryn Stephenson, M.D.* Science and Policy Consultant, and Professor University of Malaya Assistant Professor of Medicine School of Medicine Department of Medicine University of California, San Francisco Lee Ratner, M.D., Ph.D. Beth Israel Deaconess Medical Center Professor David Bloom, Ph.D. Department of Medicine Mario Stevenson, Ph.D. Clarence James Gamble Professor of Economics Washington University School of Medicine Professor of Medicine and Demography Chief, Division of Infectious Diseases Department of Global Health and Population Andrew Rice, Ph.D. University of Miami Leonard M. Miller School Harvard T.H. Chan School of Public Health Professor of Medicine Boston, MA Department of Molecular Virology and Microbiology Baylor College of Medicine

19 Tim Brown, Ph.D. Senior Fellow MANAGEMENT GROUP The East-West Center Honolulu, HI Kevin Robert Frost Daniel Douek, M.D., Ph.D. Chief Executive Officer Chief, Human Immunology Section Vaccine Research Center Anthony Ancona National Institute of Allergy and Infectious Vice President and Director, Human Resources Diseases Susan J. Blumenthal, M.D., M.P.A. National Institutes of Health Senior Policy and Medical Advisor Daria J. Hazuda, Ph.D. Bradley Jensen Vice President, Scientific Affairs for Infectious Chief Financial Officer Disease Merck & Company, Inc. Rowena Johnston, Ph.D. West Point, PA Vice President and Director, Research Jeffrey Laurence, M.D. Katherine Luzuriaga, M.D. Senior Scientific Consultant for Programs Professor, Molecular Medicine, Pediatrics and Medicine Gregorio Millett, M.P.H. University of Massachusetts Medical School Vice President and Director, Public Policy Worcester, MA Eric Muscatell Kenneth H. Mayer, M.D. Vice President, Development Infectious Disease Attending and Director of HIV AnnMari Shannahan Prevention Research Vice President, Public Information Beth Israel Deaconess Medical Center Annette Sohn, M.D. Professor of Medicine Vice President and Director, TREAT Asia Harvard Medical School

Medical Research Director and Co-Chair The Fenway Institute/Fenway Health

Jeffrey L. Sturchio, Ph.D. President and Chief Executive Officer Rabin Martin, NYC

Visiting Scholar The Institute for Applied Economics, Global Health and the Study of Business Enterprise Johns Hopkins University

Member The Council on Foreign Relations

Phill Wilson Member amfAR Board of Trustees

Founder and Chief Executive Officer (Retired) The Black AIDS Institute Los Angeles, CA

20 20 amfAR, The Foundation for AIDS Research

NEW YORK 120 Wall Street, 13th Floor New York, NY 10005-3908 (212) 806-1600 (tel) (212) 806-1601 (fax)

WASHINGTON, D.C. 1100 Vermont Avenue, NW Suite 600 Washington, DC 20005 (202) 331-8600 (tel) (202) 331-8606 (fax)

BANGKOK, THAILAND TREAT Asia Exchange Tower 388 Sukhumvit Road, Suite 2104 Klongtoey, Bangkok 10110 Thailand +66 (0)2 663 7561 (tel) +66 (0)2 663 7562 (fax)

www.amfar.org

amfAR meets the BBB Wise Giving Alliance’s Standards for Charity Accountability.